Compare LYFT Inc (LYFT) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LYFT Inc vs Sana Biotechnology Inc — how do they compare? LYFT Inc trades at $16.28 (market cap $6.11B), while Sana Biotechnology Inc trades at $2.84 (market cap $836.71M). The key difference: LYFT Inc is far larger — about 7.3× Sana Biotechnology Inc's market cap, and LYFT Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold LYFT Inc for 47 Days and Sana Biotechnology Inc for 23 Days on average.
| LYFT | SANA | |
|---|---|---|
Market Cap | $6.11B | $836.71M |
Volume | 13,504,560 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $24.57 | $5.92 |
52-Week Low | $12.65 | $2.68 |
Typical Hold Time | 47 Days | 23 Days |
Enterprise Value | $5.57B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lyft trades at $15.60, down 1.02% on the day, with a bullish technical outlook supported by moving averages despite recent earnings misses. The company shows strong profitability with 45.52% gross margins and 42.32% net income margin, while recent developments include European expansion and a $272.5M legal settlement. Cash flow has improved significantly, with operating cash flow reaching $1.17B in 2025.
Lyft presents a mixed investment case with attractive valuation metrics (P/E 2.35, P/S 0.96) but faces execution risks from recent earnings misses and competitive pressures. The 36.67% analyst buy rating and $18.07 consensus target suggest moderate upside potential, though regulatory concerns and market volatility remain key risks.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
